All companies
Visit website
WinSanTor
OperatingBiotech
Ensuring no one suffers from Peripheral Neuropathy
Valuation cap ⓘ
$500.0M
As of Apr 2024 · from WINSANTOR Future Equity SAFE 1 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$764,151
Across 3 rounds since 2018
Financials
FY2016–FY2024 · from SEC filings · hover any figure for its source$1.1M
−$140K
2016
$1.6M
−$870K
2017
$1.6M
−$870K
2018
$1.2M
−$2.1M
2019
$7.2M
−$833K
2021
$11.9M
−$1.9M
2022
$5.6M
−$3.0M
2023
$0
−$1.0M
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2016
FY2017
FY2018
FY2019
FY2021
FY2022
FY2023
FY2024
Income statement
Revenue
$1,101,422
$1,558,270
$1,558,270
$1,181,568
$7,235,609
$11,945,627
$5,621,391
$0
Cost of goods sold
$0
$0
$0
$0
$1,036,219
$404,904
$0
$0
Gross margin
100%
100%
100%
100%
86%
97%
100%
—
Net income
-$139,770
-$870,392
-$870,392
-$2,124,767
-$832,913
-$1,899,492
-$3,041,283
-$1,043,027
Taxes paid
$1,375
-$168,163
-$168,163
-$70,923
$0
$0
$0
$0
Balance sheet
Cash
$44,191
$109,627
$109,627
$31,888
$446,574
$576,026
$49,679
$18,528
Accounts receivable
$1,661
$1,577
$1,577
$0
$1
$245,623
$0
$0
Total assets
$211,697
$116,234
$116,234
$35,500
$454,257
$941,494
$183,269
$249,835
Short-term debt
$221,474
$220,465
$220,465
$1,386,502
$2,227,726
$7,823,666
$9,681,079
$6,767,767
Long-term debt
$425,000
$0
$0
$325,000
$3,584,968
$61,496
$15,371
$0
Total liabilities
$646,474
$220,465
$220,465
$1,711,502
$5,812,694
$7,885,162
$9,696,450
$6,767,767
Other
Headcount
—
5
8
5
—
11
—
1
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$75.0M
Valuation cap
$500.0M
Valuation cap
Reg CF Offering (2020)
WINSANTOR Future Equity SAFE 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $191.5K / $618KInvestors 52Valuation cap $500M
Raised $0 / $535KInvestors 0Valuation cap $75M
Reg CF Offering (2018)Withdrawn
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 3 of 8 annual reports (FY2018–FY2025)
52 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 10 filings on EDGARSource: ManualCIK 0001611161
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.